Eli Lilly (LLY) stock is in focus as Zepbound succeeds in a late-stage trial for patients with plaque psoriasis. Read more ...

The Cabinet of Ministers has set a state order for domestic passenger transportation by rail at UAH 16 billion in 2026. The ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 20 years. On February 18, Eli Lilly announced positive topline results from the Phase 3b TOGETHER-PsO trial, which ...

Combination ixekizumab plus tirzepatide outperformed ixekizumab monotherapy for the treatment of both psoriasis and ...

The results of 2 recent clinical trials combining the GLP-1 drug and the biologic reinforce the benefits of treating obesity and inflammation together.

US drugmaker Eli Lilly has announced positive topline results from the landmark TOGETHER-PsO open-label Phase IIIb trial ...

Eli Lilly and Co. LLY on Wednesday shared topline results from the landmark TOGETHER-PsO open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) ...

Join the Princeton Symphony Orchestra at the Princeton Public Library for an insightful discussion on musical composition with Julian Grant and Mahan Esfahani. The event, part of the free Soundtracks ...

New findings indicate that in adults with moderate-to-severe plaque psoriasis who are overweight or obese, combined treatment with ixekizumab (Taltz) and tirzepatide (Zepbound) results ...

At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance ...

A charity representing cancer patients has said it expects a ‘move toward resolution’ when it meets the Transport Minister.